Why does the pre-travel consultation need to happen 6–8 weeks before departure?

Many destination-specific vaccines require a two-dose primary course separated by weeks — hepatitis A (standard 2-dose, 6–12 months apart; accelerated available), hepatitis B (3-dose series 0/1/6 months, or accelerated 0/7/21 days with 12-month booster), rabies pre-exposure prophylaxis (3 doses at 0, 7, and 21 or 28 days), and tick-borne encephalitis. Mefloquine requires a 2–3 week loading period for tolerance. Allowing 6–8 weeks also provides time for immunity to develop before exposure and for managing any side effects before departure. Last-minute travellers can still benefit — abbreviated consultations using combination vaccines and accelerated schedules reduce but do not eliminate risk.

Which countries require a yellow fever vaccination certificate for entry?

Yellow fever vaccination is the only vaccine with International Health Regulations (IHR) entry requirements — certain countries mandate proof of vaccination for travellers arriving from yellow fever endemic regions (parts of sub-Saharan Africa and tropical South America) or for direct travel from endemic zones. The requirement list is updated regularly by the WHO. Always check the [Smartraveller](https://www.smartraveller.gov.au) destination advisory and the WHO entry requirements for the specific countries on the itinerary. Yellow fever vaccine (Stamaril) must be administered at a designated yellow fever vaccination centre in Australia and documented with an International Certificate of Vaccination or Prophylaxis — a single dose is lifelong protection since the 2016 WHO policy change.

What are the options for malaria chemoprophylaxis and how do I choose?

Choice depends on the destination's Plasmodium species and resistance patterns, traveller factors, and cost. Atovaquone-proguanil (Malarone) is first-line in most settings — taken daily, starting 1–2 days before travel and continuing for 7 days post-return; well-tolerated; suitable in pregnancy only after specialist advice. Doxycycline 100 mg daily is the cost-effective alternative — start 1–2 days before, continue 4 weeks after return; photosensitivity and GI side effects; reduces OCP efficacy. Mefloquine 250 mg weekly is convenient for longer trips but is contraindicated in psychiatric history, seizure disorder, and cardiac conduction abnormalities — start 2–3 weeks before. Chloroquine is now rarely used due to widespread resistance.

What should a GP prescribe for traveller's diarrhoea?

Traveller's diarrhoea affects 30–50% of travellers to high-risk destinations. Prevention relies on food and water hygiene — 'Boil it, cook it, peel it, or forget it' — not antibiotic prophylaxis (resistance concerns and side effects outweigh benefit). A standby antibiotic is appropriate for most travellers to South Asia, Southeast Asia, sub-Saharan Africa, and Latin America: azithromycin 1 g as a single dose (or 500 mg daily for 1–3 days for moderate-severe illness) is first-line in Australia. Loperamide controls symptoms but not the infection — use as adjunct, avoid in febrile diarrhoea. Oral rehydration salts are the cornerstone of management. ORS sachets (Gastrolyte, Hydralyte) should be in the travel kit.

How should I manage a patient returning from overseas with fever?

Fever in a returned traveller from a malaria-endemic area is malaria until proven otherwise — this is the most important principle in returned traveller assessment. Malaria can present without typical features; Plasmodium falciparum can be fatal within hours. Order malaria thick and thin blood films plus a rapid diagnostic test (RDT); if clinical suspicion is high and initial films are negative, repeat in 12–24 hours. Other important diagnoses by region: dengue (NS1 antigen + IgM, particularly South-East Asia, Pacific), typhoid (blood culture), rickettsial diseases (from Africa or Asia), leptospirosis (after water exposure), and viral haemorrhagic fevers in travellers from West Africa. Refer to an infectious disease specialist for complex or atypical presentations.

Travel medicine — pre-travel consultation

Travel medicine: pre-travel consultation guide for Australian GPs

By Dr HB Lo, FACRRM Reviewed 23 June 2026 10 min read

A pre-travel consultation — ideally 6–8 weeks before departure — assesses traveller and destination risk factors, updates routine vaccines, prescribes destination-specific vaccines and chemoprophylaxis, and provides behavioural counselling. Yellow fever vaccination is required by International Health Regulations for entry to certain countries and must be given at a designated centre.

Malaria prophylaxis is destination-specific: atovaquone-proguanil is first-line, doxycycline is cost-effective, mefloquine is avoided in psychiatric or seizure history. Azithromycin standby addresses traveller's diarrhoea; acetazolamide prevents altitude illness above 2,500 m.

Approximately 11 million Australians travel internationally each year. Most return without significant illness, but preventable travel-related infections — malaria, typhoid, hepatitis A, vaccine-preventable diseases — cause substantial morbidity and occasional mortality. The pre-travel consultation is the GP’s opportunity to significantly reduce that risk. The Australasian Society for Infectious Diseases (ASID) and International Society of Travel Medicine (ISTM) both recommend a structured, risk-stratified approach covering traveller factors, destination characteristics, and matched interventions. Ideally the consultation occurs 6–8 weeks before departure; even last-minute travel benefits from abbreviated assessment.

A. Core clinical — the AU general-practice framework

Pre-travel risk assessment

Traveller factors to assess:

Age — paediatric and elderly considerations; physiological reserve
Chronic conditions — cardiovascular disease, diabetes, respiratory disease, renal impairment, immunocompromise
Pregnancy — live vaccines contraindicated; Zika destinations require specific counselling; fitness-to-fly by gestation
Current medications — interactions with chemoprophylaxis (mefloquine + psychotropics, doxycycline + OCP, atovaquone-proguanil + rifampicin)
Psychiatric history — mefloquine contraindication
Mental health — anxiety about travel, health anxiety, pre-existing treatment plans
Mobility and disability — DVT risk, accessibility
Purpose of travel — tourism, business, VFR (visiting friends and relatives — typically higher-risk), adventure/wilderness, humanitarian, mission

Destination factors to assess:

Specific countries and regions within countries
Urban vs rural vs remote — risk profile differs substantially
Season — wet season raises vector-borne disease risk; pilgrimages (Hajj) have specific requirements
Accommodation type — hotel (lower risk) vs hostel/camping/village accommodation (higher)
Planned activities — water exposure, animal contact, altitude, sexual activity
Duration — short-term vs extended stay
Healthcare access at destination

Vaccination strategy

Routine catch-up — update at every pre-travel consultation regardless of destination:

dTpa if >10 years since last dose
MMR if not 2-dose immune
Varicella if not immune
Influenza (seasonal)
COVID-19 per current ATAGI recommendations
HPV for eligible adolescents and young adults
Polio (IPV) booster for travellers to Pakistan, Afghanistan, and Niger

Required vaccinations — International Health Regulations (IHR) entry requirement:

Yellow fever (Stamaril): Sub-Saharan African and tropical South American endemic zones; some countries require proof of vaccination for all arrivals or for arrivals from endemic countries. Single dose provides lifelong protection since 2016. Must be administered at a designated yellow fever vaccination centre in Australia and documented on an International Certificate of Vaccination or Prophylaxis.

Recommended vaccinations — destination-specific:

Vaccine	Route / Schedule	Key destinations
Hepatitis A (Havrix, Vaqta)	2 doses, 6–12 months apart (accelerated available)	All developing-country travel with food/water exposure
Hepatitis B (Engerix-B)	3 doses (0/1/6 months) or accelerated; check NIP status	Longer stays, healthcare workers
Typhoid (Typhim Vi injectable or Vivotif oral Ty21a)	Vi: single dose; Ty21a: 3 doses alternate days	South Asia, sub-Saharan Africa, parts of Latin America
Cholera (Dukoral oral)	2 doses, 1 week apart	High-risk or outbreak areas
Japanese encephalitis (Imojev or JEspect)	1–2 doses	Rural/endemic Asia; after 2022 Australian outbreaks — some rural Queensland risk
Rabies pre-exposure (HDCV, Verorab)	3 doses: Days 0, 7, 21 or 28	Remote travel, cave exploration, animal contact, veterinary workers
Meningococcal ACWY (Menactra, Nimenrix)	Single dose	Hajj and Umrah — Saudi Arabia entry requirement within 3 years
Tick-borne encephalitis (FSME-IMMUN)	2–3 doses	Eastern Europe, Russia, parts of Asia; outdoor activities

Malaria chemoprophylaxis

Selection depends on destination (Plasmodium species, resistance patterns), duration, and traveller factors. Consult the Australian Immunisation Handbook travel chapter or CDC Yellow Book for country-specific maps.

Agent	Dosing	Start	Stop	Notes
Atovaquone-proguanil (Malarone)	Daily	1–2 days before	7 days after	First-line; well-tolerated; expensive; not in pregnancy
Doxycycline	100 mg daily	1–2 days before	4 weeks after	Cost-effective; photosensitivity; GI effects; reduces OCP efficacy
Mefloquine (Lariam)	250 mg weekly	2–3 weeks before	4 weeks after	Convenient for long trips; neuropsychiatric SE; contraindicated in psychiatric/seizure/cardiac conduction
Primaquine	30 mg daily	1 day before	7 days after	G6PD testing mandatory first; mainly Plasmodium vivax areas
Chloroquine	Weekly	1–2 weeks before	4 weeks after	Rarely used — widespread resistance; still used in limited chloroquine-sensitive areas

B. Traveller’s diarrhoea, altitude illness, and DVT

Traveller’s diarrhoea

Affects 30–50% of travellers to high-risk destinations. The cornerstone of prevention is food and water hygiene — “Boil it, cook it, peel it, or forget it”. Antibiotic prophylaxis is not routinely recommended (resistance selection, side effects, cost).

Self-treatment kit for moderate-to-severe diarrhoea:

Azithromycin 1 g single dose (or 500 mg daily × 1–3 days) — first-line treatment in Australia; particularly important in South and Southeast Asia where quinolone resistance is widespread in Campylobacter
Loperamide — controls symptoms; avoid in febrile diarrhoea or bloody stool
Oral rehydration salts (ORS — Gastrolyte, Hydralyte) — always in the travel kit

Ciprofloxacin or azithromycin as standby; GPs can prescribe both. Fluoroquinolone resistance is now very high in South and Southeast Asia.

Altitude illness

Risk begins above 2,500–3,000 m. Acute mountain sickness (AMS), high-altitude pulmonary oedema (HAPE), and high-altitude cerebral oedema (HACE) exist on a spectrum.

Gradual ascent — ascend no more than 300–500 m per day above 3,000 m; “climb high, sleep low”
Adequate hydration; avoid alcohol and sedatives
Acetazolamide 125–250 mg twice daily — start the day before ascent; continue for 2 days at altitude; inhibits carbonic anhydrase and accelerates respiratory acclimatisation; caution in sulfa allergy; not in pregnancy
Dexamethasone 4 mg every 12 hours — alternative for those unable to take acetazolamide, or for rescue AMS treatment
Severe AMS / HAPE / HACE — descend immediately; oxygen if available; portable hyperbaric chamber (Gamow bag) if descent delayed

DVT prevention in long-haul flights

Immobility, dehydration, reduced cabin pressure, and cramped positioning all increase venous thromboembolism risk. For low-risk travellers, hydration and in-flight mobility are sufficient. For higher-risk travellers (prior DVT, active malignancy, pregnancy, recent surgery, thrombophilia, BMI >30, age >60):

Class II graduated compression hosiery — strongly recommended
Pharmacological prophylaxis (LMWH) for very high-risk — specialist guidance required

C. Behavioural counselling and returning traveller assessment

Behavioural advice (all travellers)

Mosquito and vector avoidance — foundational for malaria, dengue, Japanese encephalitis, Zika, Ross River, Barmah Forest:

DEET 20–50% or picaridin 20% applied to exposed skin
Permethrin-treated clothing and bed nets
Long sleeves and long trousers during peak vector activity periods (dusk and dawn for most Anopheles; daytime for Aedes dengue/Zika vectors)
Screened, air-conditioned accommodation where possible

Food and water safety: Avoid tap water, ice, raw vegetables, unpasteurised dairy, undercooked meat and seafood, and street food of uncertain hygiene. Bottled or boiled water; hot well-cooked food.

Sexual health: STI prevalence is higher in many destinations. Counsel on condom availability and correct use, emergency contraception, PrEP for anticipated HIV-risk sexual activity (pre-travel prescription), and STI testing on return. HIV PrEP can be initiated pre-travel and managed through the GP.

Animal contact: Avoid handling animals — particularly dogs, bats, and monkeys — in rabies-endemic countries. Pre-exposure rabies vaccination (3-dose series) is recommended for high-risk activities, remote travel, and veterinary or lab work in endemic areas.

Road safety: Road traffic injury is the leading cause of preventable death and serious injury during travel. Counsel on seat belt use, helmet use for motorcycles, avoiding drinking and driving, and the risk of night driving in countries with poor road infrastructure.

Travel insurance: Comprehensive travel insurance including medical evacuation cover is essential and should be confirmed before departure.

Returning traveller assessment

Fever within 1 year of returning from a malaria-endemic area = malaria until proven otherwise. Even partial chemoprophylaxis or prior immunity does not exclude malaria. Order malaria thick and thin blood films plus RDT immediately; repeat at 12–24 hours if initial films are negative and clinical suspicion remains.

Presentation	Key diagnoses	Workup
Fever	Malaria, dengue, typhoid, viral encephalitis, rickettsia	Films + RDT; dengue NS1 + IgM; blood culture (typhoid); consider IGRA
Diarrhoea	Bacterial (Campylobacter, Salmonella, Shigella), parasitic (Giardia, Entamoeba)	Stool MC&S; ova, cysts, parasites
Skin lesion	Cutaneous larva migrans, myiasis, leishmaniasis, scrub typhus	Dermatology or infectious disease referral
Eosinophilia	Schistosomiasis, strongyloidiasis, filariasis	Serology; stool examination
Jaundice	Hepatitis A/E, malaria, leptospirosis	LFTs, viral hepatitis serology, films + RDT

Refer to an infectious disease or tropical medicine specialist for atypical, complex, or severe presentations.

D. Australian operations

MBS items for travel medicine

There is no specific travel medicine MBS item. Travel consultations are billed as standard GP consultations:

Item 23 (Level B, <20 min) — brief update for low-risk destination
Item 36 (Level C, 20–40 min) — comprehensive pre-travel for moderate complexity
Item 44 (Level D, >40 min) — complex pre-travel (pregnancy, immunocompromise, multiple destinations)
Item 11700 — ECG (if mefloquine being considered and cardiac history)

Travel vaccines and chemoprophylaxis are typically privately purchased. Some vaccines are partially or fully funded in specific circumstances (e.g., meningococcal ACWY for Hajj may attract a gap; hepatitis B in high-risk groups on NIP).

PBS — chemoprophylaxis and travel treatment

Atovaquone-proguanil (Malarone) — General Schedule
Doxycycline — General Schedule
Mefloquine (Lariam) — General Schedule
Primaquine — Authority Required for radical cure (Plasmodium vivax or P. ovale)
Tafenoquine (Krintafel) — Authority Required; G6PD testing mandatory
Acetazolamide (Diamox) — General Schedule
Azithromycin — General Schedule
Ciprofloxacin — General Schedule
Loperamide — General Schedule (also OTC)

Designated yellow fever vaccination centres

Yellow fever vaccine must be administered at a designated yellow fever vaccination centre — the list is maintained by the Australian Department of Health. Not all GP practices are designated. The International Certificate of Vaccination or Prophylaxis (yellow card) must be signed and stamped by the authorised vaccinator on the day of vaccination.

Key Australian resources for clinicians and patients

Smartraveller (DFAT) — destination-specific health and safety advisories, updated regularly
Australian Immunisation Handbook — Travel chapter — vaccine schedules and indications
CDC Yellow Book — comprehensive country-by-country reference
ASID Travel Medicine resources — Australian infectious diseases specialist guidance
ISTM GeoSentinel — returning traveller disease surveillance

E. Special populations

Pregnancy: Avoid live vaccines (MMR, varicella, yellow fever — relative contraindication; case-by-case specialist assessment; injectable typhoid Vi safe, oral Ty21a avoid). Malaria in pregnancy carries severe risk of severe disease, miscarriage, and preterm birth — chloroquine-sensitive malaria: chloroquine safe; most endemic areas now chloroquine-resistant; mefloquine after first trimester is generally acceptable with specialist advice; avoid atovaquone-proguanil and doxycycline. Zika destinations: avoid entirely during pregnancy and for 2 months pre-conception for male and 2 months for female travellers. Fitness-to-fly: most airlines allow up to 36 weeks for uncomplicated singleton pregnancy.

Immunocompromised travellers: Live vaccines generally contraindicated — yellow fever, MMR, varicella, oral typhoid, oral polio. Yellow fever risk-benefit for travel to endemic areas requires infectious disease or travel medicine specialist consultation. Inactivated vaccines are safe but may produce lower titres — consider boosters and post-vaccination serology where relevant.

VFR travellers (visiting friends and relatives): VFR travellers — Australian residents travelling to their country of origin — carry the highest overall burden of travel-related infection. They are frequently assumed (by themselves and sometimes clinicians) to have retained immunity; they often stay in private homes rather than hotels; and they are frequently less compliant with prophylaxis. Emphasise that risk is real and that prophylaxis is just as important as for first-time travellers.

Children: Ensure childhood vaccinations are current. Age-appropriate mosquito repellent (DEET from 2 months; picaridin per product instructions). Paediatric dosing for malaria prophylaxis. GI dehydration risk is higher — carry ORS. Altitude illness can present atypically in children.

When to escalate

Refer or escalate when:

Complex pre-travel assessment (pregnancy, severe immunocompromise, multiple destinations) — travel medicine specialist or infectious disease clinic
Yellow fever vaccination required in a patient with immunocompromise, HIV, egg allergy, or thymus disease — specialist review for risk-benefit
Returned traveller with fever from malaria-endemic area not responding to initial assessment — emergency or infectious disease
Unusual post-travel illness (eosinophilia, jaundice, atypical neurological features) — infectious disease or tropical medicine specialist
Notifiable disease on return (malaria, dengue, typhoid, viral haemorrhagic fever) — state or territory public health unit notification mandatory

What this article is and is not

This is general health information derived from the Australian Immunisation Handbook travel chapter, eTG, ASID, ISTM, and Smartraveller. It is not personal medical advice and does not create a doctor–patient relationship. Pre-travel recommendations are destination-specific and updated as disease patterns and outbreaks change — always verify against current Smartraveller advisories and the Handbook before the consultation.

For patient-facing information: Smartraveller, HealthDirect — Travel health.

Sources cited

Frequently asked questions

Why does the pre-travel consultation need to happen 6–8 weeks before departure?

Many destination-specific vaccines require a two-dose primary course separated by weeks — hepatitis A (standard 2-dose, 6–12 months apart; accelerated available), hepatitis B (3-dose series 0/1/6 months, or accelerated 0/7/21 days with 12-month booster), rabies pre-exposure prophylaxis (3 doses at 0, 7, and 21 or 28 days), and tick-borne encephalitis. Mefloquine requires a 2–3 week loading period for tolerance. Allowing 6–8 weeks also provides time for immunity to develop before exposure and for managing any side effects before departure. Last-minute travellers can still benefit — abbreviated consultations using combination vaccines and accelerated schedules reduce but do not eliminate risk.
Which countries require a yellow fever vaccination certificate for entry?

Yellow fever vaccination is the only vaccine with International Health Regulations (IHR) entry requirements — certain countries mandate proof of vaccination for travellers arriving from yellow fever endemic regions (parts of sub-Saharan Africa and tropical South America) or for direct travel from endemic zones. The requirement list is updated regularly by the WHO. Always check the [Smartraveller](https://www.smartraveller.gov.au) destination advisory and the WHO entry requirements for the specific countries on the itinerary. Yellow fever vaccine (Stamaril) must be administered at a designated yellow fever vaccination centre in Australia and documented with an International Certificate of Vaccination or Prophylaxis — a single dose is lifelong protection since the 2016 WHO policy change.
What are the options for malaria chemoprophylaxis and how do I choose?

Choice depends on the destination's Plasmodium species and resistance patterns, traveller factors, and cost. Atovaquone-proguanil (Malarone) is first-line in most settings — taken daily, starting 1–2 days before travel and continuing for 7 days post-return; well-tolerated; suitable in pregnancy only after specialist advice. Doxycycline 100 mg daily is the cost-effective alternative — start 1–2 days before, continue 4 weeks after return; photosensitivity and GI side effects; reduces OCP efficacy. Mefloquine 250 mg weekly is convenient for longer trips but is contraindicated in psychiatric history, seizure disorder, and cardiac conduction abnormalities — start 2–3 weeks before. Chloroquine is now rarely used due to widespread resistance.
What should a GP prescribe for traveller's diarrhoea?

Traveller's diarrhoea affects 30–50% of travellers to high-risk destinations. Prevention relies on food and water hygiene — 'Boil it, cook it, peel it, or forget it' — not antibiotic prophylaxis (resistance concerns and side effects outweigh benefit). A standby antibiotic is appropriate for most travellers to South Asia, Southeast Asia, sub-Saharan Africa, and Latin America: azithromycin 1 g as a single dose (or 500 mg daily for 1–3 days for moderate-severe illness) is first-line in Australia. Loperamide controls symptoms but not the infection — use as adjunct, avoid in febrile diarrhoea. Oral rehydration salts are the cornerstone of management. ORS sachets (Gastrolyte, Hydralyte) should be in the travel kit.
How should I manage a patient returning from overseas with fever?

Fever in a returned traveller from a malaria-endemic area is malaria until proven otherwise — this is the most important principle in returned traveller assessment. Malaria can present without typical features; Plasmodium falciparum can be fatal within hours. Order malaria thick and thin blood films plus a rapid diagnostic test (RDT); if clinical suspicion is high and initial films are negative, repeat in 12–24 hours. Other important diagnoses by region: dengue (NS1 antigen + IgM, particularly South-East Asia, Pacific), typhoid (blood culture), rickettsial diseases (from Africa or Asia), leptospirosis (after water exposure), and viral haemorrhagic fevers in travellers from West Africa. Refer to an infectious disease specialist for complex or atypical presentations.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.

T1 AU primary 7 sources
T2 International primary 1 source
- International Society of Travel Medicine (ISTM)
T4 Contrarian — examined 2 sources
- CDC Yellow Book — Health Information for International Travel
- WHO International Travel and Health